CSWM
YMAB

Cassady Schiller Wealth Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Cassady Schiller Wealth Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-525
Closed -$9K – 625
2021
Q4 		$9K Buy
+525
New +$11.2K 0.01% 326

Other funds holding YMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Cassady Schiller Wealth Management's YMAB Position: Q1 2022 in Review

Cassady Schiller Wealth Management sold out of Y-mAbs Therapeutics (YMAB) in Q1 2022, closing a stake of 525 shares — an estimated $9K sold.

Cassady Schiller Wealth Management first reported a position in YMAB in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

  • Cassady Schiller Wealth Management reported no remaining Y-mAbs Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Cassady Schiller Wealth Management sold 525 Y-mAbs Therapeutics shares in Q1 2022, an estimated $9K.
  • Cassady Schiller Wealth Management first reported a position in Y-mAbs Therapeutics in Q4 2021 and held it in 1 quarter.
  • Cassady Schiller Wealth Management's Y-mAbs Therapeutics position peaked at $9K in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Cassady Schiller Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.